Liquidia (NASDAQ:LQDA) Stock Price Up 3.1% on Analyst Upgrade

Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) rose 3.1% during mid-day trading on Thursday after Wells Fargo & Company raised their price target on the stock from $23.00 to $25.00. Wells Fargo & Company currently has an overweight rating on the stock. Liquidia traded as high as $14.71 and last traded at $14.57. Approximately 617,093 shares traded hands during trading, a decline of 48% from the average daily volume of 1,189,840 shares. The stock had previously closed at $14.13.

Other research analysts have also issued research reports about the company. HC Wainwright lifted their target price on Liquidia from $29.00 to $35.00 and gave the stock a "buy" rating in a research report on Wednesday, May 28th. Oppenheimer set a $13.00 target price on Liquidia and gave the stock an "underperform" rating in a research report on Monday, May 19th. Scotiabank lifted their target price on Liquidia from $36.00 to $37.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, May 28th. Wall Street Zen upgraded Liquidia from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Needham & Company LLC reiterated a "buy" rating on shares of Liquidia in a research report on Monday, June 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Liquidia presently has an average rating of "Moderate Buy" and a consensus target price of $26.89.

Insider Activity at Liquidia

In other Liquidia news, insider Jason Adair sold 1,856 shares of the business's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now owns 184,304 shares in the company, valued at approximately $2,501,005.28. The trade was a 1.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rajeev Saggar sold 2,450 shares of the business's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the transaction, the insider now owns 263,152 shares of the company's stock, valued at $3,597,287.84. This trade represents a 0.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,138 shares of company stock worth $450,233 in the last 90 days. 26.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LQDA. Rhumbline Advisers boosted its position in Liquidia by 3.5% during the 4th quarter. Rhumbline Advisers now owns 80,652 shares of the company's stock worth $948,000 after acquiring an additional 2,741 shares during the period. Sigma Planning Corp boosted its position in Liquidia by 3.4% during the 4th quarter. Sigma Planning Corp now owns 65,210 shares of the company's stock worth $767,000 after acquiring an additional 2,115 shares during the period. Bank of New York Mellon Corp boosted its position in Liquidia by 3.3% during the 4th quarter. Bank of New York Mellon Corp now owns 188,584 shares of the company's stock worth $2,218,000 after acquiring an additional 6,034 shares during the period. Steward Partners Investment Advisory LLC bought a new stake in shares of Liquidia in the 4th quarter worth $59,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Liquidia by 9.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company's stock worth $5,040,000 after buying an additional 38,313 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Stock Performance

The stock has a 50 day moving average price of $15.12 and a 200 day moving average price of $14.11. The company has a market cap of $1.24 billion, a P/E ratio of -8.87 and a beta of 0.04.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The firm had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.23 million. As a group, equities research analysts predict that Liquidia Co. will post -1.51 earnings per share for the current year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).